Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
Consent informed, written, signed and dated
Women or men aged 18 to 70 years inclusive
Carrier of L. loa microfilaremia
Body weight ≥ 40 kg and less than 90 kg
Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of albendazole placebo)
Any vaccination within 4 weeks previous to this study
Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment)
Known immunosuppressive pathology (by self-report)
Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Lead sponsor
Institut de Recherche pour le Developpement
Collaborator